Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics | Zendy

Lütfiye Öksüz | Zendy; Nezahat Gürler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics

Author(s) -

Lütfiye Öksüz,

Nezahat Gürler

Publication year - 2013

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.3867

Subject(s) - quinupristin , linezolid , dalfopristin , tigecycline , teicoplanin , microbiology and biotechnology , cefoxitin , methicillin resistant staphylococcus aureus , daptomycin , antibiotics , vancomycin , medicine , biology , staphylococcus aureus , bacteria , genetics

The treatment of methicillin-resistant staphylococcal infections has been a growing problem both in and out of hospitals for the past 30 years. Therefore, there is a need for other antibiotics as an alternative to glycopeptides in the treatment of methicillin-resistant staphylococcal infections. This study investigated the in vitro susceptibility of 49 methicillin-resistant Staphylococcus aureus (MRSA) and 59 methicillin-resistant coagulase negative staphylococci (MRCNS) clinical isolates to daptomiycin, telithromycin, tigecyclin, quinupristin/dalfopristin, and linezolid.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research